Avricore Health Corporate Update – Company Demonstrates Strong Growth
Avricore Health Corporate Update – Company Demonstrates Strong Growth
VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or "AVCR") reports on its third quarter results which demonstrate significant growth in pharmacy locations offering HealthTab driving strong revenue growth and operational cashflow positivity. With demand for clinical services growing in pharmacies thanks to the ever-expanding scope and demonstrated success they are having with it; the Company expects to finish the year well ahead of the year previous and have great momentum for 2024.
不列顛哥倫比亞省溫哥華,2023 年 11 月 30 日(GLOBE NEWSWIRE)— AVRICORE HEALTH INC.多倫多證券交易所股票代碼:AVCR)(“公司” 或 “AVCR”)報告了其第三季度業績,這些業績顯示,提供HealthTab的藥房顯著增長,推動了強勁的收入增長和運營現金流的積極性。由於範圍不斷擴大,藥房對臨床服務的需求不斷增長,並取得了成功;該公司預計今年年底將遠遠領先於上年,並在2024年保持強勁勢頭。
"Patients and pharmacists are discovering and accessing new information that's having a powerful impact on their care and support thanks to HealthTab," said Hector Bremner, CEO of Avricore Health Inc. "Our ambition of helping more people live better is becoming reality each day and we are poised to make big breakthroughs in bringing this service to more patients around the world."
Avricore Health Inc.首席執行官赫克託·佈雷姆納說:“藉助HealthTab,患者和藥劑師正在發現和訪問對他們的護理和支持產生巨大影響的新信息。我們幫助更多人生活得更美好的願望每天都在變爲現實,我們準備在將這項服務提供給全球更多患者方面取得重大突破。”
Revenues and Operational Net-Positive Results Grow
收入和運營淨利好業績增長
Trends are still yet to be established with respect to test usage and system deployment cadence, the two primary ways the company generates revenues. The Company is not only pioneering the first turnkey solution for point-of-care testing and health data insights, but policy and funding within Canada and other nations to support this type of work in pharmacies is being implemented in real-time. However, year-over-year revenue comparisons are demonstrating strong gross revenue increases, while the Company's fiscal discipline is leading to ever-increasing net-cashflow, despite significant investment in the HealthTab network growth.
測試使用和系統部署節奏的趨勢仍有待確定,這是公司創收的兩種主要方式。該公司不僅率先推出了首個用於即時檢測和健康數據洞察的統包解決方案,而且加拿大和其他國家正在實時實施支持藥房此類工作的政策和資金。但是,同比收入比較表明,總收入增長強勁,而儘管對HealthTab網絡增長進行了大量投資,但該公司的財政紀律仍導致淨現金流不斷增加。
In the three months ended September 30, 2023 revenue increased by 27% year-over-year to $953,454 and gross profit increased by 21% to $261,778. In the nine months ended September 30, 2023 revenue increased by 169% year-over-year to $2,130,744 and gross profit increased by 144% to $701,930.
在截至2023年9月30日的三個月中,收入同比增長27%,達到953,454美元,毛利增長21%,達到261,778美元。在截至2023年9月30日的九個月中,收入同比增長169%,達到2,130,744美元,毛利增長144%,達到701,930美元。
While a non-cash item, stock-based compensation, made up most of the Company's expenses leading to a net loss thus far, it's important to recognize that a $412,400 net positive cashflow from operations was achieved, representing an increase in cash from operations of $825,960 over 2022.
儘管股票薪酬這一非現金項目構成了公司迄今爲止導致淨虧損的大部分支出,但重要的是要認識到,運營產生的淨正現金流爲412,400美元,這意味着運營現金比2022年增加了825,960美元。
For additional perspective on the positive fiscal track of the Company, consider that the Company achieved a 169% increase over 2022 nine-months revenues and a 144% increase in gross profit over the same period with operating expenses (excluding stock-based compensation) only increasing by 16%.
要進一步了解公司的積極財務狀況,請考慮公司在2022年九個月的收入中增長了169%,毛利同期增長了144%,運營費用(不包括股票薪酬)僅增長了16%。
All of this means the Company is growing rapidly and remains in a confident position to meet future demand.
所有這些都意味着公司正在快速增長,並且仍然有信心滿足未來的需求。
Looking Ahead
展望未來
The Company has previously announced new programs and partnerships where work is ongoing. The team expects significant growth and new revenue opportunities in the year ahead as these opportunities mature. These include:
該公司此前已宣佈了新的計劃和合作夥伴關係,這些計劃和合作夥伴關係仍在進行中。該團隊預計,隨着這些機會的成熟,來年將出現顯著增長和新的收入機會。其中包括:
- Being selected by Barts Heart Centre and national cardiovascular charity HEART UK to assess the feasibility of community pharmacists in the UK's ability to complement opportunistic blood pressure checks with cholesterol testing to assess overall cardiovascular risk and build on the clinical services offered.
- Ascensia Diabetes Care, a global diabetes care company, to integrate their blood glucose monitoring (BGM) systems, marketed as CONTOURNEXT GEN and CONTOURNEXT ONE, with HealthTab and bringing near-to-patient data into HealthTab results.
- Launching with Rexall Pharmacies, one of Canada's largest and most respected pharmacy brands, the second national chain to roll out HealthTab.
- 被Barts Heart Center和全國心血管慈善機構HEART UK選中,負責評估英國社區藥劑師是否有能力將機會性血壓檢查與膽固醇測試相輔相成,以評估整體心血管風險並在所提供的臨床服務基礎上再接再厲。
- 全球糖尿病護理公司Ascensia Diabetes Care將把他們的血糖監測(BGM)系統(以CONTOURNEXT GEN和CONTOURNEXT ONE的名義銷售)與HealthTab整合,並將接近患者的數據納入HealthTab的結果中。
- 與加拿大最大和最受尊敬的藥房品牌之一Rexall Pharmacies共同推出,這是第二家推出HealthTab的全國連鎖藥房。
The Company continues many other interesting and potentially exciting conversations as it seeks to drive greater collaboration between various parties interested in patient health, both within Canada and internationally.
該公司繼續進行許多其他有趣且可能令人興奮的對話,以期推動加拿大國內和國際上對患者健康感興趣的各方之間加強合作。
2023 Objectives |
Further expansion of HealthTab with current partners. (Update: There are currently 703 participating Shoppers Drug Mart pharmacies and Loblaw family stores offering screening tests to patients via HealthTab) |
Expansion of HT in other pharmacy groups in Canada. (Update The Company recently announced Rexall Pharmacies is beginning to take HealthTab systems and looks forward to working with them.) |
International expansion. (Update: The Company is excited to learn more and drive demand for HealthTab in the UK and beyond, this work is in progress.) |
Hiring key positions to support technical and business development efforts. (Update: Adding a team member last year has been sufficient to date in terms of personnel, and the use of AI tools allows the Company to drive productivity while effectively managing expenses. The team is constantly reviewing human resources needs and has an action plan in place to grow the team on an as-needed basis.) |
Revenue growth and profitability. (Update: The company's revenues and gross profitability continue to trend in the right direction and considering the ever-rising numbers of systems, test demand and potential for more public funding aimed at pharmacy, the Company is very confident in its long-term goals. |
2023 年目標 |
與現有合作伙伴一起進一步擴展HealthTab。 (更新: 目前有703家參與的Shoppers Drug Mart藥房和Loblaw家族門店(通過HealthTab向患者提供篩查測試) |
將HT擴展到加拿大其他藥房集團。 (更新 該公司最近宣佈,Rexall Pharmacies開始採用HealthTab系統,並期待與他們合作。) |
國際擴張。 (更新: 該公司很高興能了解更多信息並推動英國及其他地區對HealthTab的需求,這項工作正在進行中。) |
招聘關鍵職位以支持技術和業務發展工作。 (更新: 迄今爲止,就人員而言,去年增加一名團隊成員已經足夠了,人工智能工具的使用使公司能夠在有效管理開支的同時提高生產力。該團隊不斷審查人力資源需求,並制定了行動計劃,以根據需要擴大團隊。) |
收入增長和盈利能力。 (更新: 該公司的收入和總盈利能力繼續朝着正確的方向發展,考慮到系統數量的不斷增加、測試需求以及針對藥房的更多公共資金的潛力,該公司對其長期目標充滿信心。 |
HealthTab Market Fast Facts
HealthTab 市場速覽
- Point of Care Testing Market to reach $93.21 Billion USD in 2030 (Source)
- Nearly 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed (Source)
- Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
- Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it's only after a heart attack they are diagnosed. (Source)
- There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.
- 即時護理測試市場將在2030年達到932.1億美元(來源)
- 預計到2030年將有近1360萬加拿大人患有糖尿病或糖尿病前期,其中許多人未被診斷(來源)
- 超過三分之一的美國人(約8,800萬人)患有糖尿病前期(來源)
- 每年有將近16萬名20歲及以上的加拿大人被診斷出患有心臟病,通常是在心臟病發作後才被診斷出患有心臟病。(來源)
- 加拿大有超過10,000家藥房,美國有88,000家藥房,英國有近12,000家。
About HealthTab
關於健康選項卡
HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.
HealthTab 是一站式即時醫療測試解決方案,它將一流的即時醫療技術與安全的基於雲的平台相結合,用於解決緊迫的全球健康問題。只需從手指刺中滴下幾滴血,該系統即可當場生成實驗室準確的結果,並實時報告數據。測試菜單包括多達23種關鍵生物標誌物,用於篩查和管理慢性病,例如糖尿病和心臟病(例如HbA1c、脂質譜、eGFR)。HealthTab 最近還增加了細菌和病毒檢測功能,例如鏈球菌和 COVID-19。
HealthTab網絡模型與當今藥房中的任何模型都不一樣。它讓知識淵博、值得信賴的藥劑師在初級保健提供中發揮更大的作用,同時使患者能夠更好地控制自己的健康。它還降低了成本和等待時間,並提供了許多潛在的收入來源,包括設備租賃和消耗品、直接訪問測試、疾病預防和管理計劃、贊助的健康計劃、分散的臨床試驗、真實世界數據 (RWD) 集以及通過API進行第三方應用程序集成。
About Avricore Health Inc.
關於 Avricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab, a wholly owned subsidiary, the Company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.
Avricore Health Inc.(多倫多證券交易所股票代碼:AVCR)是一家藥房服務創新者,專注於收購和開發旨在推動藥房向前發展的早期技術。通過其旗艦產品HealthTab(一家全資子公司),該公司的使命是通過在社區藥房創建世界上最大的快速檢測設備網絡,讓所有人更容易獲得可操作的健康信息。
Contact:
聯繫人:
Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
Avricore Health Inc
赫克託·佈雷姆納,首席執行官 604-773-8943
info@avricorehealth.com
Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
關於前瞻性陳述的警示說明
本新聞稿中涉及Avricore Health對未來的預期、計劃、意圖或戰略的信息均爲前瞻性陳述,不是事實,涉及許多風險和不確定性。Avricore Health 通常使用諸如 “展望”、“將”、“可能”、“可能”、“保留”、“未來”、“計劃”、“相信”、“可能”、“期望”、“打算”、“預期”、“估計”、“未來”、“定位”、“潛在”、“項目”、“保留”、“計劃”、“計劃”、“計劃”、“計劃”、“計劃”、“計劃”、“設定”、“設定”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“定位”、“計劃”、“計劃”” “受制於”、“即將到來” 和類似的表述,以幫助識別前瞻性陳述。在本新聞稿中,前瞻性陳述包括以下方面的陳述:配售的完成及其預期時間以及公司對配售收益的預期用途;HealthTab平台爲藥劑師和患者提供的獨特功能。前瞻性陳述反映了Avricore Health管理層當時的預期、信念、假設、估計和預測。本新聞稿中的前瞻性陳述基於Avricore Health截至本新聞稿發佈之日獲得的信息。前瞻性陳述被認爲是真實的,最終可能會被證明是不正確的。這些聲明不能保證Avricore Health的未來表現,並且受一些風險、不確定性和其他因素的影響,其中一些因素是其無法控制的,可能導致實際業績與當前的預期存在重大差異,包括但不限於:未能滿足監管要求;市場變化;經濟狀況的潛在衰退;以及Avricore公開文件中描述的其他風險因素。這些前瞻性陳述僅代表其發表之日,除非法律另有要求,否則公司沒有義務公開更新這些陳述以反映新信息或未來事件或情況的發生。
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多倫多證券交易所風險交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對充分性或準確性承擔責任 此版本的。